News Search Results
Mar 06, 2025, 07:00 ET Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.
Mar 06, 2025, 07:00 ET Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
decades of extensive international experience across both start-ups and large global organizations within the life sciences, pharmaceutical, and biotechnology sectors. "On behalf of Evogene, I am pleased to welcome Nir Nimrodi as the new Chairperson of the Board,"
More news about: Evogene
Mar 06, 2025, 06:45 ET Microfiltration Membranes Market worth $2.16 billion by 2029 - Exclusive Report by MarketsandMarkets™
wastewater and water treatment, heightened concern for water shortage, and stricter environmental regulations. Food & beverage, pharmaceuticals, and biotechnology industries are also fueling growth as these sectors need high-purity filtration to ensure product quality and safety. Furthermore, advancements
More news about: MarketsandMarkets
Mar 06, 2025, 05:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Public Limited Company Lawsuit - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Mar 06, 2025, 04:00 ET GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy
6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received clearance from the U.S Food
More news about: GenAssist Therapeutic Co.,Ltd
Mar 05, 2025, 23:00 ET Fayafi Investment Holding Expands Investment Portfolio with Technology, Digital Finance and Carbon Credit Initiatives
Deploys capital towards opportunities in AI, quantum computing, digital assets, defence, biotechnology and more DUBAI, UAE, March 6, 2025
More news about: Fayafi Investment Holding
Mar 05, 2025, 23:00 ET Fayafi Investment Holding Expands Investment Portfolio with Technology, Digital Finance and Carbon Credit Initiatives
Deploys capital towards opportunities in AI, quantum computing, digital assets, defence, biotechnology and more DUBAI, UAE, March 6, 2025
More news about: Fayafi Investment Holding
Mar 05, 2025, 18:01 ET Global Biosensors Market to Show Positive Growth at a CAGR of ~8% by 2032 | DelveInsight
processes or the detection of specific molecules. Biosensors are commonly used in medical diagnostics, environmental monitoring, food safety, and biotechnology. They offer significant advantages due to their sensitivity, specificity, and ability to detect low concentrations of target analytes, making them
More news about: DelveInsight Business Research, LLP
Mar 05, 2025, 18:00 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 05, 2025, 17:46 ET Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences,
More news about: DelveInsight Business Research, LLP
Mar 05, 2025, 17:31 ET XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
Immunitas Therapeutics (IMT-009), Monte Rosa Therapeutics (MRT-2359), SymBio Pharmaceuticals (Brincidofovir (SyB V-1901)), AVM Biotechnology (AVM0703), Autolus Therapeutics (Obecabtagene Autoleucel (Obe-cel), AUTO3), Kymera Therapeutics (KT-413), Otsuka Pharmaceutical
More news about: DelveInsight Business Research, LLP
Mar 05, 2025, 14:45 ET Ability of Large Language Models to Extract PD-L1 Biomarker Details From Electronic Health Records
a Sage company is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology and life sciences, specialized clinical medicine, and public health and policy, and technology & engineering. Since its founding in 1980, the
More news about: Mary Ann Liebert, Inc.
Mar 05, 2025, 12:10 ET Anivive Expands Specialty Diagnostics Lab to Accommodate Increased Demand for Services
vidiumah.com. About Anivive Lifesciences Anivive Lifesciences is a software-driven pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable
More news about: Anivive Lifesciences Inc.
Mar 05, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Law Offices of Howard G. Smith
Mar 05, 2025, 12:00 ET New England Biolabs® Announces the 2025 Donald G. Comb Memorial Lectureship Recipient
innovative work has been used to inform new diagnostic and therapeutic approaches. Finally, Dr. Bertozzi is a prolific member of the industrial biotechnology community, having co-founded numerous companies to translate her basic science discoveries beyond the lab bench. Dr. Bertozzi has received
More news about: New England Biolabs, Inc.
Mar 05, 2025, 10:30 ET HEOR Services Market Size Booms with CAGR 12.3%, Projected to Reach $3.79 Billion by 2031 | Exclusive Report by The Insight Partners
the HEOR Services market is segmented into healthcare providers, healthcare payers, biotech/pharma companies, and government organizations. The biotechnology and pharmaceutical companies segment held the largest share of the HEOR services market in 2024.The HEOR services market is segmented into
More news about: The Insight Partners
Mar 05, 2025, 08:33 ET CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors to Inquire About a Securities Fraud Class Action by March 10, 2025
CLICK HERE. Regeneron, headquartered in Tarrytown, NY, is a biotechnology company that designs products for eye diseases, inflammatory diseases, cancer, and cardiovascular and metabolic diseases. On April
More news about: Berger Montague
Mar 05, 2025, 08:30 ET Momentum Biotechnologies Announces Acquisition of OmicScouts
end-to-end solutions tailored to project-specific needs, and the team has a strong track record of successful collaborations with top pharmaceutical and biotechnology companies. To learn more, visit
More news about: Momentum Biotechnologies
Mar 05, 2025, 08:30 ET TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding
More news about: TC BioPharm
Mar 05, 2025, 08:00 ET Arthrosi Therapeutics Completes Enrollment in Pivotal Phase 3 REDUCE 2 Trial of AR882 for the Treatment of Gout and Tophaceous Gout
DIEGO, March 5, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Mar 05, 2025, 07:30 ET Virax Biolabs to Present at 19th World Immune Regulation Meeting
March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present
More news about: Virax Biolabs
Mar 05, 2025, 07:00 ET Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access
Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), today announced that Ramesh
More news about: Nanoscope Therapeutics
Mar 05, 2025, 07:00 ET SanyouBio Launches 73 Whole-Series Bispecific Reference Antibody Products, Facilitating New Breakthroughs in Bispecific Drug Development
paving the way for a brighter future." About Sanyou BioSanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated
More news about: Sanyou Bio
Mar 05, 2025, 06:55 ET PFAS Testing Market worth US$969.5 million by 2030 with 14.5% CAGR | MarketsandMarkets™
different applications. The firm is continually building on its portfolio by adding new mass spectrometry and chromatography consumables for specific biotechnology, pharmaceutical, toxicology, forensic, and other applications. In February 2022, Thermo Fisher
More news about: MarketsandMarkets
Mar 04, 2025, 22:38 ET Avecho i Sandoz zawarły wyłączną umowę licencyjną i dotyczącą opracowania preparatu CBD na bezsenność w celu jego komercjalizacji w Australii
MELBOURNE, Australia, 5 marca 2025 r. /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) („Avecho" lub „Firma") ogłosiła dzisiaj, że zawarła dziesięcioletnią umowę licencyjną i na opracowanie preparatu z Sandoz Group
More news about: Avecho Biotechnology